Long-term safety and disease control with Ruxolitinib cream in atopic dermatitis: Pooled results from two phase 3 studies

被引：0

作者：

Papp, K. ^{[1
]}

Szepietowski, J. C. ^{[2
]}

Kircik, L. ^{[3
]}

Toth, D. ^{[4
]}

Eichenfield, L. F. ^{[5
,6
]}

Forman, S. B. ^{[7
]}

Kuligowski, M. E. ^{[8
]}

Venturanza, M. E. ^{[8
]}

Ren, H. ^{[8
]}

Simpson, E. L. ^{[9
]}

机构：

[1] K Papp Clin Res & Prob Med Res, Waterloo, ON, Canada

[2] Wroclaw Med Univ, Dept Dermatol Venereol & Allergol, Wroclaw, Poland

[3] Icahn Sch Med Mt Sinai, New York, NY USA

[4] XLR8 Med Res & Prob Med Res, Windsor, ON, Canada

[5] Univ Calif San Diego, Dept Dermatol, San Diego, CA 92103 USA

[6] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA

[7] ForCare Clin Res, Tampa, FL USA

[8] Incyte Corp, Wilmington, NC USA

[9] Oregon Hlth & Sci Univ, Portland, OR USA

来源：

EXPERIMENTAL DERMATOLOGY | 2021年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：43 / 43

页数：1

共 50 条

[31] Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies
Lisa Bloudek
Lawrence F. Eichenfield
Jonathan I. Silverberg
Vijay N. Joish
Jennifer H. Lofland
Kang Sun
Matthias Augustin
Kristen Migliaccio-Walle
Sean D. Sullivan
American Journal of Clinical Dermatology, 2023, 24 : 109 - 117
[32] Effects of ruxolitinib cream in patients with atopic dermatitis with baseline body surface area ≥10% and Eczema Area and Severity Index score ≥16: Pooled results from two phase 3 studies
Simpson, Eric L.
Kircik, Leon
Blauvelt, Andrew
Kuligowski, Michael E.
Venturanza, May E.
Sun, Kang
Eichenfield, Lawrence F.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB157 - AB157
[33] Tapinarof cream for the treatment of atopic dermatitis: Efficacy and safety results from two Japanese phase 3 trials
Igarashi, Atsuyuki
Tsuji, Gaku
Fukasawa, Shuichi
Murata, Ryusei
Yamane, Satoshi
JOURNAL OF DERMATOLOGY, 2024, 51 (11): : 1404 - 1413
[34] Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies
Xiaohua Gong
Xuejun Chen
Michael E. Kuligowski
Xing Liu
Xiang Liu
Evan Cimino
Ryan McGee
Swamy Yeleswaram
American Journal of Clinical Dermatology, 2021, 22 : 555 - 566
[35] Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies
Gong, Xiaohua
Chen, Xuejun
Kuligowski, Michael E.
Liu, Xing
Liu, Xiang
Cimino, Evan
McGee, Ryan
Yeleswaram, Swamy
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2021, 22 (04) : 555 - 566
[36] Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children
Wahn, U
Bos, JD
Goodfield, M
Caputo, R
Papp, K
Manjra, A
Dobozy, A
Paul, C
Molloy, S
Hultsch, T
Graeber, M
Cherill, R
de Prost, Y
PEDIATRICS, 2002, 110 (01) : e2
[37] Efficacy and Safety of Ruxolitinib Cream in Vitiligo by Patient Characteristic Subgroups: Descriptive Pooled Analysis From Two Phase 3 Studies
Seneschal, Julien
Wolkerstorfer, Albert
Desai, Seemal R.
Grimes, Pearl
Ezzedine, Khaled
Pandya, Amit G.
Kornacki, Deanna
Wei, Shaoceng
Passeron, Thierry
Rosmarin, David
DERMATOLOGY AND THERAPY, 2025, : 1227 - 1238
[38] Reducing the itchiness associated with atopic dermatitis: results from two long-term nemolizumab studies
不详
BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E177 - E177
[39] Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis
Meurer, M
Fartasch, M
Albrecht, G
Vogt, T
Worm, M
Ruzicka, T
Altmeyer, PJ
Schneider, D
Weidinger, G
Braeutigam, M
DERMATOLOGY, 2004, 208 (04) : 365 - 372
[40] Long-term disease control in atopic dermatitis using biologics
Thyssen, Jacob P.
Schmid-Grendelmeier, Peter
LANCET, 2023, 401 (10372): : 172 - 173

← 1 2 3 4 5 →